Delving into the Latest Updates on Fuzheng Jiedu Huayu Principle with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms

Fu Zheng Jie Du Hua Yu Principle

Target-

Mechanism-

Therapeutic Areas

NeoplasmsInfectious DiseasesDigestive System Disorders

Active Indication-

Inactive Indication

Hepatitis BHepatitis B Virus-Related Hepatocellular Carcinoma

Originator Organization

Beijing Ditan Hospital

Active Organization-

Inactive Organization

Beijing Ditan Hospital

Drug Highest PhasePendingEarly Phase 1

First Approval Date-

Regulation-

Login to view timeline

In the current study, bioinformatics analysis of the hepatocellular carcinoma (HCC) dataset was conducted with the hepatoprotective effect of the Fuzheng Huayu (FZHY) capsule against the diethylnitrosamine-induced HCC progression analyzed. Eight cell clusters were defined and tanshinone IIA, arachidonic acid, and quercetin, compounds of the FZHY capsule, inhibit HCC progression-related fibrosis by regulating the expression of PLAU and IGFBP3. Combined with the ameliorative effect of the FZHY capsule against liver dysfunctions and expression of PLAU and IGFBP3, our study confirmed the effect of the FZHY capsule on inhibiting the fibrosis-associated HCC progression via regulating the expression of PLAU and IGFBP3.

07 Jun 2024·Medicine

Congenital hepatic fibrosis with negative endoscopic evaluation of esophageal and gastric varices: A case report

Article

Author: Pan, Lin ; Shao, Huaguo

Rational:Congenital hepatic fibrosis (CHF) is a rare autosomal recessive genetic disease, which is often diagnosed in children and young adults. The clinical manifestations of CHF were lack of specificity, mainly including portal hypertension related symptoms and signs, and normal or mildly abnormal liver function. When no obvious varices are indicated under endoscope, it can easily lead to misdiagnosis or missed diagnosis. We report this case in the hope of raising awareness of this disease.Patient concerns:A 31 years old male patient with major clinical manifestations of unexplained thrombocytopenia for 5 years.Diagnoses:Results of ultrasound, magnetic resonance imaging (MRI) and computed tomography portal venography (CTV) showed that patient had liver cirrhosis with portal hypertension and liver biopsy revealed CHF.Intervention:Patient received ursodeoxycholic acid tablets, fuzheng huayu capsule, ganshuang granule, etc for liver protection treatment.Outcomes:The condition of patient stabilized after symptomatic treatment. Spleen resection will be considered during follow-up.Lessons:This case reminds us that in case of patients with negative endoscopic evaluation, ultrasonic, computed tomography (CT) and MRI examination should be performed at the same time to determine whether patients have portal hypertension. When patients with normal or mildly abnormal liver function had unexplained liver cirrhosis complicated with portal hypertension, the possibility of CHF should be considered.

28 May 2024·Journal of Clinical and Translational Hepatology

Beneficial Effects of Traditional Chinese Medicine Fuzheng Huayu on the Occurrence of Hepatocellular Carcinoma in Patients with Compensated Chronic Hepatitis B Cirrhosis Receiving Entecavir: A Multicenter Retrospective Cohort Study

Article

Author: Wang, Hui ; Liu, Chenghai ; Shen, Xizhong ; Fan, Haina ; Huang, Jiaquan ; Lei, Shujuan ; Li, Xiaodong ; Mei, Yang ; Liu, Xudong ; Zhu, Chuanwu ; Zhao, Zhimin ; Zhang, Wei ; Xu, Min ; Sun, Kewei ; Huang, Yan ; Zhang, Kejun ; Xing, Huichun ; Xie, Qing ; Zong, Yali

Background and AimsThe application of antifibrotic drugs to treat patients with chronic liver diseases who are receiving antiviral therapies for hepatocellular carcinoma (HCC) has not been established. Here, we aimed to assess the impact of the Traditional Chinese Medicine Fuzheng Huayu (FZHY) on the occurrence of HCC in patients with hepatitis B virus-related compensated cirrhosis receiving the antiviral drug entecavir (ETV).MethodsA multicenter retrospective cohort study was performed. Compensated liver cirrhosis patients were divided into the ETV+FZHY group or the ETV group according to treatment. The cumulative incidence of HCC was analyzed using Kaplan-Meier and log-rank tests. Propensity score matching was used for confounding factors. Stratified analysis and Cox regression were used to determine the effects of FZHY on the occurrence of HCC and liver function decompensation.ResultsOut of 910 chronic hepatitis B patients, 458 were in the ETV+FZHY group and 452 were in the ETV group. After propensity score matching, the 5-year cumulative incidence of HCC was 9.8% in the ETV+FZHY group and 21.8% in the ETV group (p<0.01). The adjusted hazard ratio for HCC was 0.216 (0.108, 0.432) when FZHY treatment was >36 months. Age, diabetes, alanine aminotransferase, γ-glutamyl transpeptidase, albumin, hepatitis B e-antigen, and fibrosis 4 score were associated with the occurrence of HCC. FZHY decreased the risk of HCC in patients aged >45 years with a hepatitis B virus DNA level of ≥2,000 IU/l.ConclusionAdjunctive FZHY treatment reduced HCC occurrence in patients with hepatitis B virus cirrhosis who were treated with ETV, possibly due to the antifibrotic properties of FZHY.

100 Deals associated with Fuzheng Jiedu Huayu Principle

Login to view more data